Tumor Immunotherapy and Microenvironment (TIME)

activities

Cancer immunotherapy has emerged as a revolutionary treatment for many aggressive cancers for which conventional therapies have failed. However, this enthusiastic vision has been seriously challenged by clinical data indicating that only a few numbers of patients benefit from durable clinical remissions, while the majority have a short-term benefit or no benefit at all.

The strategic priority of TIME group relies on discovering druggable targets in tumor cells and pathways in the tumor microenvironment that are able to improve the benefit of cancer immunotherapy by reprogramming cold immune desert tumors into hot inflamed immune infiltrated tumors.

Therefore, TIME research activities are at the forefront of translating basic knowledge into clinical application. To fulfill the strategic priority and strengthen the translational aspect of its research activities, TIME group has established collaboration with leading cancer centers in Europe and biotech and pharma companies.

The ultimate aim of the TIME group is to address the unmet clinical needs by providing the proof of concept to set up innovative clinical trials, which take full advantage of the impressive value of cancer immunotherapy.